SARS-CoV-2 Antibody Detection and Quantification
The detection of antibodies to SARS-Cov-2 in whole blood, serum or plasma samples is an indication of previous infection with the virus. As information about the antibody response to this virus increases, the clinical utility of laboratory and point of care tests will become clearer.
Serological testing is a useful tool in the surveillance of the infection and in determining the extent of the COVID-19 pandemic. It may also be helpful for the diagnosis of patients with a negative PCR result or for the identification of patients that have had asymptomatic infections.
Oxford Biosystems has 3 kits available for point of care antibody detection in whole blood from a finger-prick sample. These kits are not designed for home use and are available for professional use only in the UK and Republic of Ireland. The results should be interpreted in conjunction with the clinical history of the individual, any previous exposure to the infection and the onset of any relevant symptoms. It has been shown that seroconversion rates are variable and it is recommended that samples for antibody detection are collected at least 2-3 weeks after onset of symptoms.
SD Biosensor Standard Q COVID-19 IgM/IgG Combo
SD Biosensor Standard F COVID-19 IgM/IgG Combo FIA
The investigation of the antibody response to SARS-CoV-2 in a laboratory setting may involve the measurement of IgG, IgM and IgA antibodies, as well as the specific targets of these antibodies.
Coronaviruses contain at least 4 structural proteins:
- Spike (S) protein
- Envelope (E) protein
- Membrane (M) protein
- Nucleocapsid (N) protein
The investigation may include specific antibody quantification to more than one target protein.
Oxford Biosystems is working with several manufacturers to provide a range of products that cover a variety of options.
||Anti-SARS-CoV-2-S1 (RBD) ELISA
||Standard E COVID-19 Total Ab ELISA
||Novel Coronavirus COVID-19 IgG ELISA
||Novel Coronavirus COVID-19 IgM ELISA
||SARS-CoV-2 Human IgG (4-plex)
TestLine Clinical Diagnostics, a Czech company and part of the BioVendor Group, has developed a range of ELISA kits for the determination of IgG, IgM and IgA antibodies against SARS-CoV-2 (COVID-19) in human serum or plasma. These kits are also available as SmartEIA kits, specifically designed for automated analysis using the Dynex Agility ELISA instrument.
For further information please contact us directly or visit the TestLine website